TEVA REMINDER: Investors With Losses In Excess of $1,000,000 Are Reminded to Contact the Rosen Law Firm Regarding the Important January 5 Deadline in Class Action Filed by Firm- TEVA
27 déc. 2016 09h00 HE
|
The Rosen Law Firm PA
NEW YORK, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the American Depositary Shares (“ADSs”) of Teva Pharmaceutical Industries Limited...
Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited - TEVA
12 déc. 2016 18h23 HE
|
The Rosen Law Firm PA
NEW YORK, Dec. 12, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the American Depositary...
Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Teva Pharmaceutical Industries Limited (NYSE: TEVA) Securities Case
08 déc. 2016 11h06 HE
|
Scott + Scott, Attorneys at Law, LLP
NEW YORK, Dec. 08, 2016 (GLOBE NEWSWIRE) -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 5, 2017 is the last day to...
Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Teva Pharmaceutical Industries Limited (NYSE: TEVA) Securities Case
08 nov. 2016 10h53 HE
|
Scott + Scott, Attorneys at Law, LLP
NEW YORK, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 5, 2017 is the last day to file...
Agile Therapeutics Reports First Quarter 2016 Financial Results
09 mai 2016 16h10 HE
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations through the End of 2017Clinical Trial Expected to Complete in Fourth Quarter 2016 and Resubmission Planned for First Half 2017 PRINCETON, N.J., May 09, 2016 ...
Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies
02 févr. 2016 08h00 HE
|
AbCellera
JERUSALEM and VANCOUVER, British Columbia, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and AbCellera have entered into a collaborative research...
Phase 2 Trial Results Show Mesoblast Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure
29 sept. 2015 21h10 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC:MBLTY) today announced that additional Phase 2 trial results of its lead product candidate for...
Mesoblast Unveils Path to Bring Its Key Products to Market
25 août 2014 20h27 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported 2014 financial results and unveiled its...
Mesoblast Reports Strong Half-Year Financial Results
25 févr. 2014 17h00 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided its 2014 half-year financial results and...
FDA CLEARS COMMENCEMENT OF PHASE 3 CHRONIC HEART FAILURE TRIAL USING MESOBLAST'S PROPRIETARY CELLS
30 oct. 2013 18h41 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the United States Food and Drug...